Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

Abstract Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland. Methods Ret...

Full description

Bibliographic Details
Published in:BMC Infectious Diseases
Main Authors: Myriam Drysdale, Holly Tibble, Vishal Patel, Daniel C. Gibbons, Emily J. Lloyd, William Kerr, Calum Macdonald, Helen J. Birch, Aziz Sheikh
Format: Article
Language:English
Published: BMC 2024-07-01
Subjects:
COVID-19
Sotrovimab
Molnupiravir
Nirmatrelvir/ritonavir
Omicron BA.1
Omicron BA.2
Online Access:https://doi.org/10.1186/s12879-024-09576-7

Internet

https://doi.org/10.1186/s12879-024-09576-7

Similar Items